Drug intelligence / Profile preview

RM801

Development stage: Preclinical
Lead developer: Guangzhou Reforgene Medicine
Modality: Gene Therapies

Overview

RM801 is an *in vivo* gene-editing therapeutic candidate being developed by Guangzhou Reforgene Medicine for the treatment of cardiovascular and hepatic diseases. Currently in the preclinical stage, the program utilizes gene-editing technology to address undisclosed genetic targets within the liver or cardiovascular system. As an *in vivo* therapy, it is designed to perform genetic modifications directly within the patient's body, aiming to provide a durable therapeutic effect for chronic or hereditary conditions.

Beyond the preview

Go deeper on RM801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RM801.

Explore the full profile